Cingulate Inc. (CING) vs Heron Therapeutics, Inc. (HRTX)
A side-by-side comparison of Cingulate Inc. and Heron Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CING
Cingulate Inc.
$4.91HealthcareDelayed quote: Oct 6, 2026, 3:34 PM EDT
HRTX
Heron Therapeutics, Inc.
$0.33HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — CING vs HRTX
growth of $100 · dividends reinvested · last 5yCING -99.6% (-66.1%/yr)HRTX -95.6% (-46.4%/yr)HRTX compounded faster over this window
Log scale — wide-divergence pair
CING HRTX
CING vs HRTX: by the numbers
- •CING is the larger company ($66M vs $62M market cap).
- •Both run net losses; CING's is the smaller (0.00% vs -22.52% net margin).
Metrics side by side
Valuation
| Metric | CING | HRTX |
|---|---|---|
| P/S ratio | N/A | 0.41 |
| P/B ratio | 2.82 | 10.58 |
| EV / EBITDA | 0.23 | N/A |
Profitability
| Metric | CING | HRTX |
|---|---|---|
| Gross margin | 0.00% | 70.07% |
| Operating margin | 0.00% | -7.19% |
| Net margin | 0.00% | -22.52% |
| ROE | -122.71% | -492.89% |
| ROIC | -83.74% | -6.79% |
Growth (annualized)
| Metric | CING | HRTX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 12.73% |
| Total return CAGR (5Y) | N/A | -48.61% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.